This file photo provided by Celltrion Inc. shows its biosimilar Avtozma. (Yonhap)
SEOUL, Dec. 12 (Korea Bizwire) — Celltrion Inc. said Friday that its autoimmune biosimilar Avtozma has been added to the preferred drug list of Synergie Collective, one of the five largest pharmacy benefit managers in the United States—an endorsement that could significantly widen the drug’s market access.
The South Korean biopharmaceutical company said the agreement will place the intravenous formulation of Avtozma on Synergie’s insurance formularies. The move deepens Celltrion’s presence in the U.S. market, where five of its other biosimilars—Steqeyma, Yuflyma, Zymfentra, Vegzelma and Stoboclo-Osenvelt—have already secured preferred status with major PBMs.
PBMs exert outsized influence in the U.S. drug market, determining reimbursement and coverage terms for millions of patients. The top five players control more than 90% of the sector, making preferred-list access a critical commercial milestone for drugmakers.
Celltrion said the expanded lineup of PBM agreements is expected to lift earnings in the fourth quarter. The company is targeting roughly 4 trillion won (about US$2.7 billion) in revenue this year, up from 3.56 trillion won in 2024.
Ashley Song (ashley@koreabizwire.com)
